{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:14:50Z","timestamp":1789874090021,"version":"4.0.1"},"reference-count":136,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1097\/01.mcg.0000210099.36500.fe","type":"journal-article","created":{"date-parts":[[2006,4,21]],"date-time":"2006-04-21T05:02:43Z","timestamp":1145595763000},"page":"322-335","source":"Crossref","is-referenced-by-count":138,"title":["Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment Approaches"],"prefix":"10.1097","volume":"40","author":[{"given":"Gregory M.","family":"Asnis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"De La Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02893380","article-title":"Viral hepatitis: new data on hepatitis C infection","volume":"9","author":"Szab\u00f3","year":"2003","journal-title":"Pathol Oncol Res"},{"key":"R2-10-20210305","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-10-20210305","first-page":"1","article-title":"C: 2002.","volume":"19","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"R4-10-20210305","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"ASSLD practice guideline: diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"R5-10-20210305","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/13543784.11.4.515","article-title":"Developments in the treatment of chronic hepatitis C","volume":"11","author":"Pockros","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 1","key":"R6-10-20210305","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1002\/hep.510260703","article-title":"Hepatitis C: the clinical spectrum of disease","volume":"26","author":"Hoofnagle","year":"1997","journal-title":"Hepatology"},{"key":"R8-10-20210305","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R9-10-20210305","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1176\/ajp.156.7.1120","article-title":"Depression from interferon therapy in patients with hepatitis C [letter]","volume":"156","author":"Miyaoka","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R10-10-20210305","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N Engl J Med"},{"key":"R11-10-20210305","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.mp.4001119","article-title":"A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C","volume":"7","author":"Hauser","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R12-10-20210305","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-0327(02)00264-1","article-title":"Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus","volume":"72","author":"Bonaccorso","year":"2002","journal-title":"J Affect Disord"},{"key":"R13-10-20210305","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0163-8343(02)00239-6","article-title":"Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study","volume":"25","author":"Horikawa","year":"2003","journal-title":"Gen Hosp Psychiatry"},{"key":"R14-10-20210305","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1176\/appi.ajp.161.12.2332","article-title":"Interferon for hepatitis C patients with psychiatric disorders [letter]","volume":"161","author":"Asnis","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R15-10-20210305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0447.1988.tb05072.x","article-title":"Self rated depression in relation to DSM-III classification: a statistical isolinear multiple components analysis","volume":"77","author":"Maes","year":"1988","journal-title":"Acta Psychiatr Scand"},{"key":"R16-10-20210305","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1600-0447.1995.tb09613.x","article-title":"Assessment of depression: comparison between Beck Depression Inventory and subscales of Comprehensive Psychopathological Rating Scale","volume":"92","author":"Martinsen","year":"1995","journal-title":"Acta Psychiatr Scand"},{"key":"R17-10-20210305","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2893.2000.00215.x","article-title":"Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C","volume":"7","author":"Cotler","year":"2000","journal-title":"J Viral Hepat"},{"key":"R18-10-20210305","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"R19-10-20210305","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1056\/NEJM199904293401716","article-title":"Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state","volume":"340","author":"Capuron","year":"1999","journal-title":"N Engl J Med"},{"key":"R20-10-20210305","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jpsychores.2004.03.010","article-title":"Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment","volume":"58","author":"Beratis","year":"2005","journal-title":"J Psychosom Res"},{"key":"R21-10-20210305","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/gast.2002.34750","article-title":"Psychiatric disorders among veterans with hepatitis C infection","volume":"123","author":"El Serag","year":"2002","journal-title":"Gastroenterology"},{"key":"R22-10-20210305","first-page":"239","article-title":"Alpha-interferon (IFN-alpha) treatment of chronic hepatitis C: analysis of some predictive factors for the response","volume":"39","author":"Malaguarnera","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R23-10-20210305","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/107999001300177457","article-title":"Neuropsychiatric effects and type of IFN-\u03b1 in chronic hepatitis C","volume":"21","author":"Malaguarnera","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"R24-10-20210305","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.bjp.0703432","article-title":"Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test","volume":"130","author":"Makino","year":"2000","journal-title":"Br J Pharmacol"},{"key":"R25-10-20210305","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.44.1.188-a","article-title":"Interferon beta treatment of multiple sclerosis [letter]","volume":"44","author":"Klapper","year":"1994","journal-title":"Neurology"},{"key":"R26-10-20210305","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.46.2.552","article-title":"Side effect profile of interferon beta-1b in MS: results of an open label trial","volume":"46","author":"Neilley","year":"1996","journal-title":"Neurology"},{"key":"R27-10-20210305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1212\/WNL.46.1.12","article-title":"Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"R28-10-20210305","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1212\/WNL.59.5.744","article-title":"Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial","volume":"59","author":"Patten","year":"2002","journal-title":"Neurology"},{"key":"R29-10-20210305","first-page":"243","article-title":"Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial","volume":"7","author":"Patten","year":"2001","journal-title":"Mult Scler"},{"key":"R30-10-20210305","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R31-10-20210305","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1023\/A:1026625928117","article-title":"Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection","volume":"44","author":"Furusyo","year":"1999","journal-title":"Dig Dis Sci"},{"key":"R32-10-20210305","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2893.2004.00514.x","article-title":"Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients","volume":"11","author":"Cheng","year":"2004","journal-title":"J Viral Hepat"},{"key":"R33-10-20210305","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0149-2918(02)80042-X","article-title":"Pegylated interferons for the treatment of chronic hepatitis C infection","volume":"24","author":"Luxon","year":"2002","journal-title":"Clin Ther"},{"key":"R34-10-20210305","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R35-10-20210305","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R36-10-20210305","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00019053-200321050-00005","article-title":"Peginterferon alpha-2a (40kD) [Pegasys\u00ae] improves HR-QOL outcomes compared with unmodified interferon \u03b1-2a [Roferon\u00ae-A]: in patients with chronic hepatitis C","volume":"21","author":"Rasenack","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"R37-10-20210305","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-3999(00)00155-0","article-title":"Depression, fatigue, and functional disability in patients with chronic hepatitis C","volume":"49","author":"Dwight","year":"2000","journal-title":"J Psychosom Res"},{"key":"R38-10-20210305","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0168-8278(01)00280-X","article-title":"Emotional distress in chronic hepatitis C patients not receiving antiviral therapy","volume":"36","author":"Fontana","year":"2002","journal-title":"J Hepatol"},{"key":"R39-10-20210305","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3748\/wjg.v11.i12.1769","article-title":"Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C","volume":"11","author":"Kraus","year":"2005","journal-title":"World J Gastroenterol"},{"key":"R40-10-20210305","first-page":"1034","article-title":"Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial","volume":"24","author":"Lindsay","year":"1996","journal-title":"Hepatology"},{"key":"R41-10-20210305","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archinte.1987.00370090055011","article-title":"Psychiatric complications of long-term interferon alfa therapy","volume":"147","author":"Renault","year":"1987","journal-title":"Arch Intern Med"},{"key":"R42-10-20210305","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00006842-200105000-00007","article-title":"Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-\u03b1 treatments in cancer patients","volume":"63","author":"Capuron","year":"2001","journal-title":"Psychosom Med"},{"key":"R43-10-20210305","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"R44-10-20210305","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon \u03b1-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon \u03b12b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"R45-10-20210305","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4088\/JCP.v65n0420b","article-title":"Ribavirin may be an important factor in IFN-induced neuropsychiatric effects [letter]","volume":"65","author":"Asnis","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R46-10-20210305","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial","volume":"26","author":"Bodenheimer","year":"1997","journal-title":"Hepatology"},{"key":"R47-10-20210305","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4088\/JCP.v64n0614","article-title":"Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy","volume":"64","author":"Kraus","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R48-10-20210305","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4088\/JCP.v66n0106","article-title":"Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction","volume":"66","author":"Raison","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R49-10-20210305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S0033291799001774","article-title":"Interferons, serotonin and neurotoxicity","volume":"30","author":"Menkes","year":"2000","journal-title":"Psychol Med"},{"key":"R51-10-20210305","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000067682","article-title":"Assessment of depression in patients with chronic viral hepatitis: effect of interferon treatment","volume":"20","author":"Koskinas","year":"2002","journal-title":"Dig Dis"},{"key":"R52-10-20210305","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2796.2002.00974.x","article-title":"Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy","volume":"251","author":"Dalgard","year":"2002","journal-title":"J Intern Med"},{"key":"R53-10-20210305","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.1998.8.951","article-title":"The thyroid axis and depression","volume":"8","author":"Jackson","year":"1998","journal-title":"Thyroid"},{"key":"R54-10-20210305","doi-asserted-by":"crossref","first-page":"RC16","DOI":"10.1007\/BF03347491","article-title":"A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C","volume":"27","author":"Loftis","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"R55-10-20210305","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1086\/376908","article-title":"Implications of anemia in human immunodeficiency virus, cancer, and hepatitis C virus","volume":"37","author":"Mildvan","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R56-10-20210305","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/376911","article-title":"Anemia in the treatment of hepatitis C virus infection","volume":"37","author":"Sulkowski","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R57-10-20210305","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1093\/jn\/133.12.4139","article-title":"Low hemoglobin level is a risk factor for postpartum depression","volume":"133","author":"Corwin","year":"2003","journal-title":"J Nutr"},{"key":"R58-10-20210305","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(98)04793-X","article-title":"Treatment with interferon-\u03b1 in patients with chronic hepatitis and mood or anxiety disorders","volume":"354","author":"Pariante","year":"1999","journal-title":"Lancet"},{"key":"R59-10-20210305","first-page":"165","article-title":"Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness","volume":"7","author":"Van Thiel","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R60-10-20210305","first-page":"328","article-title":"Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease","volume":"45","author":"Van Thiel","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"R61-10-20210305","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(96)80020-1","article-title":"Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy","volume":"24","author":"Chiaramonte","year":"1996","journal-title":"J Hepatol"},{"key":"R62-10-20210305","first-page":"150","article-title":"Transmission of hepatitis C virus: a study of the main risk factors in a Sicilian population of volunteer blood donors","volume":"45","author":"Soresi","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"R63-10-20210305","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1007410707801","article-title":"Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain","volume":"14","author":"Rodriguez","year":"1998","journal-title":"Eur J Epidemiol"},{"key":"R64-10-20210305","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00042737-199906000-00010","article-title":"Hepatitis C virus infection risk factors in patients admitted in hospital emergency departments in Picardy. Value of oriented screening based on recommendations of the \u2018Direction G\u00e9n\u00e9rale de la Sant\u00e9\u2019","volume":"11","author":"Capron","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R65-10-20210305","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/j.1572-0241.2002.06042.x","article-title":"Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C","volume":"97","author":"Lehman","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R66-10-20210305","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.euroneuro.2003.08.004","article-title":"The impact of stress on addiction","volume":"13","author":"Goeders","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"R67-10-20210305","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.psy.44.2.104","article-title":"A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C","volume":"44","author":"Dieperink","year":"2003","journal-title":"Psychosomatics"},{"key":"R68-10-20210305","first-page":"29","article-title":"IFN-induced depression: a role for NSAIDs","volume":"37","author":"Asnis","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"R69-10-20210305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/10428199809068563","article-title":"The biology of interferon-alpha and the clinical significance of anti-interferon antibodies","volume":"29","author":"Hanley","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"R70-10-20210305","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/cbr.1998.13.143","article-title":"Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon","volume":"13","author":"Walter","year":"1998","journal-title":"Cancer Biother Radiopharm"},{"key":"R71-10-20210305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-1781(01)00315-8","article-title":"Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms","volume":"105","author":"Bonaccorso","year":"2001","journal-title":"Psychiatry Res"},{"key":"R72-10-20210305","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000126396","article-title":"Interferon-\u03b1 stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro","volume":"57","author":"Gisslinger","year":"1993","journal-title":"Neuroendocrinology"},{"key":"R73-10-20210305","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jir.1997.17.589","article-title":"Quinolinic acid production by macrophages stimulated with IFN-\u03b3, TNF-\u03b1, and IFN-\u03b1","volume":"17","author":"Pemberton","year":"1997","journal-title":"J Interferon Cytokine Res"},{"key":"R74-10-20210305","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/1521-4141(200108)31:8<2313::AID-IMMU2313>3.0.CO;2-S","article-title":"Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-\u03b3-independent mechanism","volume":"31","author":"Fujigaki","year":"2001","journal-title":"Eur J Immunol"},{"key":"R75-10-20210305","first-page":"11","article-title":"The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-\u03b1-induced depression","volume":"29","author":"Wichers","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"R76-10-20210305","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-200202000-00014","article-title":"Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system","volume":"22","author":"Bonaccorso","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R77-10-20210305","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.mp.4000995","article-title":"Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy","volume":"7","author":"Capuron","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R78-10-20210305","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0006-3223(03)00173-2","article-title":"Interferon-alpha\u2013induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment","volume":"54","author":"Capuron","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R79-10-20210305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molbrainres.2004.02.010","article-title":"Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy","volume":"124","author":"Yang","year":"2004","journal-title":"Mol Brain Res"},{"key":"R80-10-20210305","first-page":"S203","article-title":"Interferon-alpha treatment and serotonergic dysfunction","volume":"36","author":"Schaefer","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"R81-10-20210305","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/hup.609","article-title":"Cytokines: abnormalities in major depression and implications for pharmacological treatment","volume":"19","author":"O\u2019Brien","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"R82-10-20210305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0083-6729(04)69005-4","article-title":"CRH, stress, and major depression: a psychobiological interplay","volume":"69","author":"Claes","year":"2004","journal-title":"Vitamins Horm"},{"key":"R83-10-20210305","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1176\/appi.ajp.160.7.1342","article-title":"Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy","volume":"160","author":"Capuron","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R84-10-20210305","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1367-5931(03)00084-X","article-title":"Prolyl peptidases: a serine protease subfamily with high potential for drug discovery","volume":"7","author":"Rosenblum","year":"2003","journal-title":"Curr Opin Chem Biol"},{"key":"R85-10-20210305","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0006-3223(91)90027-J","article-title":"Decreased serum dipeptidyl peptidase IV activity in major depression","volume":"30","author":"Maes","year":"1991","journal-title":"Biol Psychiatry"},{"key":"R86-10-20210305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1996.tb10612.x","article-title":"Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs","volume":"93","author":"Maes","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"R87-10-20210305","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.mp.4000872","article-title":"Treatment with interferon-alpha (IFN \u03b1) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation","volume":"6","author":"Maes","year":"2001","journal-title":"Mol Psychiatry"},{"key":"R88-10-20210305","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.0001-690X.2003.00230.x","article-title":"Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C","volume":"109","author":"Maes","year":"2004","journal-title":"Acta Psychiatr Scand"},{"key":"R89-10-20210305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-0327(99)00081-6","article-title":"Effects of pregnancy and delivery on serum prolyl endopeptidase (PEP) activity: alterations in serum PEP are related to increased anxiety in the early puerperium and to postpartum depression","volume":"57","author":"Maes","year":"2000","journal-title":"J Affect Disord"},{"key":"R90-10-20210305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-5728(90)90051-N","article-title":"Endothelial cell expression of the intercellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis","volume":"30","author":"Wilcox","year":"1990","journal-title":"J Neuroimmunol"},{"key":"R91-10-20210305","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0165-5728(93)90070-F","article-title":"Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-\u03b1 and blood-brain barrier damage","volume":"43","author":"Sharief","year":"1993","journal-title":"J Neuroimmunol"},{"key":"R92-10-20210305","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1176\/appi.ajp.157.10.1682","article-title":"Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex","volume":"157","author":"Thomas","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R93-10-20210305","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.161.2.271","article-title":"The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes","volume":"161","author":"Lesp\u00e9rance","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R94-10-20210305","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/315265","article-title":"Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: a prognostic marker for responses to interferon treatment","volume":"181","author":"Capra","year":"2000","journal-title":"J Infect Dis"},{"key":"R95-10-20210305","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbi.2004.02.002","article-title":"Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha","volume":"18","author":"Schaefer","year":"2004","journal-title":"Brain Behav Immun"},{"key":"R96-10-20210305","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145703003766","article-title":"Nitric oxide involvement in depression during interferon-alpha therapy","volume":"6","author":"Suzuki","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"R97-10-20210305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0165-0327(00)00164-6","article-title":"Elevated plasma nitrate levels in depressive states","volume":"63","author":"Suzuki","year":"2001","journal-title":"J Affect Disord"},{"key":"R98-10-20210305","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.jcp.0000085416.08426.1d","article-title":"Paroxetine-induced increase in metabolic end products of nitric oxide","volume":"23","author":"Lara","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R99-10-20210305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-alpha: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"R100-10-20210305","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2036.2002.01265.x","article-title":"Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C","volume":"16","author":"Kraus","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R101-10-20210305","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0006-8993(95)01415-2","article-title":"Endotoxin produces a depressive-like episode in rats","volume":"711","author":"Yirmiya","year":"1996","journal-title":"Brain Res"},{"key":"R102-10-20210305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.psy.41.5.439","article-title":"Prophylactic treatment of depression induced by interferon-alpha","volume":"41","author":"Hauser","year":"2000","journal-title":"Psychosomatics"},{"key":"R103-10-20210305","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R104-10-20210305","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2893.2005.00554.x","article-title":"Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression","volume":"12","author":"Kraus","year":"2005","journal-title":"J Viral Hepat"},{"key":"R105-10-20210305","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4088\/JCP.v63n0304","article-title":"An open-label trial of citalopram for major depression in patients with hepatitis C","volume":"63","author":"Gleason","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R106-10-20210305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1176\/appi.psy.45.1.29","article-title":"Plasma levels of citalopram in depressed patients with hepatitis C","volume":"45","author":"Gleason","year":"2004","journal-title":"Psychosomatics"},{"key":"R107-10-20210305","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/archpsyc.1994.03950080076011","article-title":"Mania induced by citalopram","volume":"51","author":"Bryois","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"R108-10-20210305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0924-977X(95)00046-R","article-title":"Antidepressant induced mania in obsessive compulsive disorder","volume":"6","author":"Berk","year":"1996","journal-title":"Eur Neuropsychopharmacol"},{"key":"R109-10-20210305","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1034\/j.1600-0447.2001.00383.x","article-title":"Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders","volume":"104","author":"Ramasubbu","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"R110-10-20210305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1034\/j.1600-0447.2003.00080.x","article-title":"Sertraline-induced hypomania: a genuine side-effect","volume":"108","author":"Mendhekar","year":"2003","journal-title":"Acta Psychiatr Scand"},{"key":"R111-10-20210305","doi-asserted-by":"crossref","first-page":"ii","DOI":"10.1093\/milmed\/168.12.ii","article-title":"Escitalopram-associated mania [letter]","volume":"168","author":"Bobo","year":"2003","journal-title":"Mil Med"},{"key":"R112-10-20210305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004850-200405000-00001","article-title":"A review of acute treatments for bipolar depression","volume":"19","author":"Silverstone","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"R113-10-20210305","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1176\/jnp.9.2.273","article-title":"Manic episodes in two patients treated with interferon alpha","volume":"9","author":"Strite","year":"1997","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R114-10-20210305","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/pgmj.73.866.834","article-title":"Bipolar disorder associated with interferon-alpha treatment","volume":"73","author":"Iancu","year":"1997","journal-title":"Postgrad Med J"},{"key":"R115-10-20210305","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/archpsyc.55.1.88","article-title":"Mania induced by withdrawal of treatment with interferon alfa","volume":"55","author":"Carpiniello","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"R116-10-20210305","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0033-3182(98)71296-4","article-title":"A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C [letter]","volume":"39","author":"Monji","year":"1998","journal-title":"Psychosomatics"},{"key":"R117-10-20210305","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1440-1819.1999.00566.x","article-title":"A case of seizures 1 week after the cessation of interferon-alpha therapy (short communication)","volume":"53","author":"Seno","year":"1999","journal-title":"Psychiatry Clin Neurosci"},{"key":"R118-10-20210305","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/1097-0142(20000715)89:2<356::AID-CNCR21>3.0.CO;2-Z","article-title":"Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes","volume":"89","author":"Greenberg","year":"2000","journal-title":"Cancer"},{"key":"R119-10-20210305","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1440-1819.2002.01070.x","article-title":"Case of mania induced by withdrawal of interferon-alpha in a patient affected by bipolar disorder [letter]","volume":"56","author":"Rossi","year":"2002","journal-title":"Psychiatry Clin Neurosci"},{"key":"R120-10-20210305","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1176\/appi.ajp.161.3.429","article-title":"Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin","volume":"161","author":"Onyike","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R121-10-20210305","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1388-9842(03)00005-9","article-title":"Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin","volume":"5","author":"Serebruany","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"R122-10-20210305","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1006\/phrs.2001.0817","article-title":"Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors","volume":"43","author":"Serebruany","year":"2001","journal-title":"Pharmacol Res"},{"key":"R123-10-20210305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000079172.43229.CD","article-title":"Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction","volume":"108","author":"Sauer","year":"2003","journal-title":"Circulation"},{"key":"R124-10-20210305","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1160\/TH03-05-0330","article-title":"The influence of selective serotonin reuptake inhibitors on human platelet serotonin","volume":"91","author":"Maurer-Spurej","year":"2004","journal-title":"Thromb Haemost"},{"key":"R125-10-20210305","first-page":"309","article-title":"Retinal complications during interferon therapy for chronic hepatitis C","volume":"91","author":"Kawano","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R126-10-20210305","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1600-0676.2001.021003192.x","article-title":"Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C","volume":"21","author":"Saito","year":"2001","journal-title":"Liver"},{"key":"R127-10-20210305","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bjo.85.10.1171","article-title":"Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin","volume":"85","author":"Jain","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R128-10-20210305","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0161-6420(02)01741-4","article-title":"Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin","volume":"110","author":"Schulman","year":"2003","journal-title":"Ophthalmology"},{"key":"R129-10-20210305","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4088\/JCP.v64n1215","article-title":"A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients","volume":"64","author":"Weinrieb","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R130-10-20210305","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2004.04.058","article-title":"Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C","volume":"365","author":"Loftis","year":"2004","journal-title":"Neurosci Lett"},{"key":"R131-10-20210305","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbi.2004.05.001","article-title":"Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C","volume":"19","author":"Raison","year":"2005","journal-title":"Brain Behav Immun"},{"key":"R132-10-20210305","first-page":"1","article-title":"Management of hepatitis C","volume":"15","year":"1997","journal-title":"NIH Consens Statement"},{"key":"R133-10-20210305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1572-0241.2001.03445.x","article-title":"Treating chronic hepatitis C patients with psychiatric disorders: an uphill battle [editorial]","volume":"96","author":"Cheung","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R134-10-20210305","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJM200107193450311","article-title":"Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?","volume":"345","author":"Edlin","year":"2001","journal-title":"N Engl J Med"},{"key":"R135-10-20210305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in methadone maintenance patients: an interim analysis","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"R136-10-20210305","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","article-title":"Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?","volume":"99","author":"Schaefer","year":"2004","journal-title":"Addiction"},{"issue":"5","key":"R137-10-20210305","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1086\/427447","article-title":"Treating hepatitis C virus infection in active substance users","author":"Sylvestre","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R138-10-20210305","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2005-837813","article-title":"Depression during therapy with interferon alpha\u2014how long should an antidepressant treatment last?","volume":"38","author":"Nickel","year":"2005","journal-title":"Pharmacopsychiatry"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mcg.0000210099.36500.fe","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:26:35Z","timestamp":1785857195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-200604000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":136,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mcg.0000210099.36500.fe","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}